Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To assess the anti-tumor activity, as measured by response rate to bi-weekly pemetrexed plus
cisplatin, in chemo-naive patients with diagnosed metastatic or locally advanced
(non-resectable) urothelial cancer.